Showing: 1 - 1 of 1 RESULTS
Briefing HAVN Life Sciences Psychedelics Revive Therapeutics

Havn Life to Supply Revive Therapeutics With Psychedelic Compounds

This morning Revive Therapeutics (CSE: RVV) announced they have signed a supply agreement with Havn Life Sciences Inc. (CSE : HAVN) to source naturally-derived psychedelic compounds, such as psilocybin, for use in future investigational new drug (IND) enabling studies and clinical trials under the FDA guidelines. Commenting on the announcement, CEO Michael Frank stated, “We are excited about …